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Review Article

Endobronchial ultrasound-guided intranodal forceps biopsy
(EBUS-IFB)—technical review
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Abstract: Endobronchial ultrasound (EBUS) and transbronchial needle aspiration (TBNA) have changed
the landscape of pulmonology. Mediastinal structures beyond the confines of airway walls are visualized
in real-time with EBUS, leading to improved accuracy of tissue sampling and diagnostic yield. With the
development of various needle sizes ranging from 25-G to 19-G, the sampling of lymph nodes is becoming
easier and more commonplace. Yet, certain conditions such as sarcoidosis and lymphoma may still be
difficult to diagnose via EBUS-TBNA. Furthermore, in the age of targeted therapy, there are more demands
on EBUS-TBNA samples for molecular marker testing and next-generation sequencing. Here, we present
a complementary methodology, EBUS-guided intranodal forceps biopsy (EBUS-IFB), for tissue acquisition
that may help address these deficiencies. Specifically, we aim to propose indications, contraindications,
outline approaches in performing IFB, and provide an overview of the data for this complementary
technique.
Keywords: Endobronchial ultrasound (EBUS); transbronchial needle aspiration (TBNA); intranodal forceps
biopsy (IFB); lymphadenopathy; miniforceps biopsy
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Introduction
With the introduction of endobronchial ultrasound
(EBUS)-guided transbronchial needle aspiration (EBUSTBNA) in 2003, bronchoscopists are able to perform
guided sampling of structures next to the airways (1).
In the following decade, EBUS-TBNA has become the
standard of care for lung cancer staging, recommended
by American College of Chest Physicians (ACCP) as the
procedure of choice over mediastinoscopy (2,3). As the
technique for EBUS-TBNA becomes standardized, there
are new challenges that need to be addressed, specifically in
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the areas of tissue acquisition for molecular testing and for
the diagnosis of certain conditions, such as lymphoma and
sarcoidosis.
While initial studies using EBUS-TBNA samples to
complete molecular analysis demonstrated success rates
ranging from 83–97%, the increasing demand for tumor
tissue poses a challenge to specimen handling (4-8). Current
guidelines suggest that in the setting of mediastinal staging,
EBUS-TBNA provides adequate material for diagnostic
purposes with 3 needle passes (3). When molecular profiling
is needed, additional needle passes may be required, with
the optimal number of specimens often based on operator
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judgement and the type of molecular analysis being
performed. Furthermore, PD-L1 testing on EBUS-TBNA
samples has not been validated with any of the commercially
available platforms (9). Moreover, there is evidence to
suggest that EBUS-TBNA samples PD-L1 status are
discordant to that of the surgical resected specimen of the
primary site of lung cancer (10).
The diagnostic yield of EBUS-TBNA for sarcoidosis is
lower than that for carcinoma (3,11,12). While the diagnosis
of sarcoidosis can be enhanced with transbronchial and
endobronchial lung biopsy, these additional steps may
increase the risk of bleeding and pneumothorax (13-15).
While the diagnostic yield of EBUS-TBNA for sarcoidosis
has been reported at greater than 90% in some studies,
this result may not be representative of practices in which
experienced cytopathology services are not available.
The diagnostic yield of EBUS-TBNA for lymphoma has
been reported to be lower than that for either carcinoma or
benign conditions such as sarcoidosis. While EBUS-TBNA
may be adequate for diagnosing relapsed lymphoma, it has
not performed well with de novo lymphoma (16-18). NonHodgkin’s and Hodgkin’s lymphoma treatment depend on
specific subtyping and histologic grade. Therefore, definitive
subtyping is essential for management and requires the
evaluation of cell morphology, immunophenotype, and
tissue architecture.
EBUS-guided intranodal forceps biopsies (EBUS-IFB)
is a technique in which small miniforceps are passed into
targeted lymph nodes following EBUS-TBNA needle
puncture. The material obtained via EBUS-IFB can be
processed as a histological specimen and has been shown to
improve the overall diagnostic yield of EBUS procedures
when combined with TBNA (19-24). All authors of this
paper routinely perform EBUS-IFB in their respective
institutions. Here, we describe the technique for EBUSIFB in patients with mediastinal and hilar lymphadenopathy
and discuss indications, contraindications, technique, and
available literature for the procedure.
Intranodal forceps biopsy (IFB)
Nomenclature
IFB has been described in the literature as micro- or miniforceps biopsy (MFB), transbronchial forceps biopsy
(TBFB), and transbronchial needle forceps (TBFN) (19-24).
In this manuscript, we use the term IFB to describe the
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procedure, and propose that this more accurately reflects
the procedural elements of obtaining forceps biopsy
specimens from within a targeted lymph node.
Equipment
EBUS-IFB is performed utilizing a standard EBUS
bronchoscope, TBNA needle and 1.0-mm miniforceps
(Figure 1). While 22-gauge needles have been used for
TBNA in most EBUS-IFB procedures in the literature,
others have reported success using 19-, 21- and even
25-gauge EBUS-TBNA needles. White light bronchoscopy
is performed initially using a conventional bronchoscope for
airway inspection as per routine clinical practice.
Technique
Following EBUS-TBNA, the airway mucosa is punctured
4 to 5 times under ultrasound guidance using the EBUSTBNA needle. This creates a defect in the airway mucosa
as well as a tract for introduction of miniforceps into the
targeted lymph node. With the EBUS bronchoscope in
steady position, the aspiration needle is withdrawn from
the working channel and the miniforceps advanced into
the target under EBUS guidance. Direct endoscopic
visualization of the mucosal puncture site is often not
possible and therefore may not be a reliable landmark
for miniforceps insertion. To facilitate miniforceps
insertion into the lymph node, the operator must maintain
a consistent EBUS image of the lymph node to avoid
any rotational or cranial/caudal deviation of the EBUS
bronchoscope that may result in misalignment of the
miniforceps to the mucosal puncture site (Figure 2). In
some cases, a needle tract will be created during TBNA
puncture which may be used as a reference to guide
miniforceps insertion; alternatively, intranodal landmarks
such as hyper or hypoechoic spots may also be used as
landmarks to assist with guiding the miniforceps into the
lymph node. It may be advisable to begin miniforceps
insertion slightly proximal to the target tract as the
miniforceps may slide along the mucosa prior to entering
the mucosal defect of the target tract. If a 19-gauge needle
is used, the needle entry alone should create a tract of
sufficient size for advancing the miniforceps into the target.
Once inside the target lesion, the miniforceps are opened
and biopsy specimens are taken under continuous EBUS
surveillance (Figure 3).

J Thorac Dis 2019;11(9):4049-4058 | http://dx.doi.org/10.21037/jtd.2019.08.106

Journal of Thoracic Disease, Vol 11, No 9 September 2019

4051

A

B

C

Figure 1 Comparison of miniforceps and regular pulmonary forceps. (A) Miniforceps and regular spiked pulmonary forceps in closed
position; (B) miniforceps and regular spiked pulmonary forceps in open position; (C) comparison of the length of miniforceps verses regular
spiked pulmonary forceps.

Specimen handling

Video 1. EBUS-IFB procedure
▲
George Cheng*, Amit Mahajan, Scott Oh, Sadia
Benzaquen, Alexander Chen
Division of Pulmonary, Allergy, and Critical Care
Medicine, Duke University Hospital, Durham, NC,
USA

Figure 2 EBUS-IFB procedure (25). EBUS, endobronchial
ultrasound; IFB, intranodal forceps biopsy.
Available online: http://www.asvide.com/watch/32949
© Journal of Thoracic Disease. All rights reserved.

Specimens obtained using EBUS-TBNA are processed per
institutional protocol for cytological specimens. EBUSIFB biopsies should be processed as histology specimens
(Figure 4). Samples are placed into formalin solution for
permanent fixation or into saline for culture. Frozen section
can be performed if intraprocedural feedback is desired and
rapid on-site evaluation of EBUS-TBNA specimens is not
available (Figure 5). Touch preparations can be done with
IFB specimens for immediate on-site evaluation, though
this practice is highly variable amongst institutions. Due to
the relatively small size of IFB specimens, efforts should be
placed on tissue conservation. It is advisable to solicit input
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Figure 3 Endobronchial view and ultrasound view. (A) Endobronchial view with microforceps extended out of the working channel.
Blue arrow is indicating the mucosal defect made by TBNA; (B) miniforceps inserted into the bronchial airway wall; (C) endobronchial
ultrasound view of the miniforceps in the lymph node; (D) endobronchial ultrasound view of the opening and advancing of miniforceps in
the lymph node. TBNA, transbronchial needle aspiration.

from institutional cytologists and pathologists regarding the
preferred manner in which specimens are processed.

and hilar lymph node stations accessible via EBUS-TBNA
are accessible using EBUS-IFB.

Indications

Contraindications

EBUS-IFB is complementary to traditional EBUSTBNA, and is performed following specimen collection
with EBUS-TBNA. EBUS-IFB may be performed in any
clinical scenario in which additional tissue is requested for
purposes such as molecular marker analysis or to assist with
making a diagnosis of centrally located thoracic processes
that are amenable to EBUS-TBNA. EBUS-IFB provides
histology specimens and therefore may be used in cases
where “core” biopsy specimens are desired. All mediastinal

Contraindications to EBUS-IFB are similar to that of EBUSTBNA, generally related to patient’s fitness to undergo
bronchoscopy as well as to tolerate moderate sedation or
general anesthesia. Procedures should be avoided in patients
at high risk for pulmonary and cardiovascular decompensation
(i.e., severe refractory hypoxemia, hypotension, and
arrhythmias), bleeding (i.e., systemic anticoagulation and
thrombocytopenia), in those who are unable to give informed
consent, and in those who have had adverse reactions to
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Figure 4 Cytology of EBUS-TBNA and histology of EBUS-IFB. (A) Low magnification (H&E stain, 10×) of EBUS-TBNA 25G aspiration;
(B) high magnification (H&E stain, 40×) of EBUS-TBNA 25G aspiration; (C) low magnification (H&E stain, 10×) of EBUS-IFB; (D)
high magnification (H&E stain, 40×) of EBUS-IFB. Diagnosis was a renal cell carcinoma. EBUS, endobronchial ultrasound; TBNA,
transbronchial needle aspiration; IFB, intranodal forceps biopsy; EBUS-TBNA, EBUS-guided TBNA; EBUS-IFB, EBUS-guided IFB.
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Figure 5 Histology of EBUS-TBNA and EBUS-IFB. (A) Low magnification (H&E stain, 10×) of EBUS-TBNA 19G aspiration; (B)
high magnification (H&E stain, 40×) of EBUS-TBNA 19G aspiration; (C) low magnification (H&E stain, 10×) of EBUS-IFB; (D) high
magnification (H&E stain, 40×) of EBUS-IFB. Diagnosis was squamous cell lung cancer. EBUS, endobronchial ultrasound; TBNA,
transbronchial needle aspiration; IFB, intranodal forceps biopsy; EBUS-TBNA, EBUS-guided TBNA; EBUS-IFB, EBUS-guided IFB.
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anesthesia. As with EBUS-TBNA, systemic anticoagulation
should be discontinued prior to procedures if possible.
Safety
As a complementary procedure to EBUS-TBNA, EBUSIFB does not significantly affect the safety profile or
workflow of bronchoscopy procedures. Of approximately
300 EBUS-IFB procedures in published literature, the
overall complication rate is 1.5%, which is comparable to
the complication rate associated with EBUS-TBNA. Three
patients experienced bleeding, controlled locally without
the need for transfusion and no deaths have been associated
with the procedure. Management of bleeding from EBUSIFB is no different than that with EBUS-TBNA. Often,
observation alone allows enough time for bleeding to stop.
If needed, EBUS scope balloon can be used to occlude
the entry point in the airway wall and provide temporary
balloon tamponade to stop bleeding. Antimicrobial
prophylaxis has not been thoroughly evaluated and practice
varies across centers. The addition of EBUS-IFB does not
significantly prolong procedure time, adding on average
less than 4 minutes to EBUS-TBNA procedures in one
publication (21). While pneumomediastinum has been
reported with EBUS-TBNA, we do not recommend routine
use of CT scans in assessment, as most are self-limiting and
will resolve without intervention.
Clinical evidence
IFB was first performed without EBUS guidance in
an effort to increase diagnostic yield when paired with
conventional TBNA (19). Oki and colleagues performed
procedures on 22 consecutive patients with enlarged
subcarinal lymph nodes using a 19-gauge TBNA needle
and 1.15-mm miniforceps without ultrasound guidance.
Diagnostic tissue was obtained by IFB in 3 patients in which
TBNA was non-diagnostic. There was a single case of
pneumomediastinum (19). In 2008, Herth et al. reported
on the safety and efficacy of obtaining histologic specimens
from subcarinal lesions larger than 2.5 cm using EBUSTBNA and EBUS-IFB (20). Seventy-five patients
underwent EBUS-TBNA with 22-gauge needle, followed
by needle puncture using a 19-gauge needle through
a conventional bronchoscope. IFB was subsequently
performed through the defect made by the 19-gauge needle
using EBUS guidance, and all procedures were performed
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under general anesthesia through a rigid bronchoscope. A
specific diagnosis was made in 36% of patients using the
22-gauge needle, 49% with the 19-gauge needle, and 88%
with the IFB. The increase in diagnostic yield with IFB
was most pronounced in patients with sarcoidosis (88% vs.
36%, P=0.001) and lymphoma (81% vs. 35%, P=0.038),
and no complications were noted (20). In 2011, Chrissian
and colleagues prospectively evaluated EBUS-TBNA and
EBUS-IFB in 74 lymph node stations in 50 patients. The
overall diagnostic yield was 81% and 91%, for EBUSTBNA and EBUS-IFB respectively (21). The overall
diagnostic yield combining both modalities was 97%, which
was a statistically significant improvement compared with
performing EBUS-TBNA alone (P<0.001). There were no
complications and the addition of EBUS-IFB to EBUSTBNA did not significantly lengthen procedure time (21).
A recent study examined 91 patients who underwent both
EBUS-TBNA and EBUS-IFB noted that EBUS-IFB
lead to additional pathologic diagnosis in 16.2% of nondiagnostic EBUS-TBNA samples, of which 66% were
non-caseating granulomas (26). Interestingly, Bramley
et al. reported the combined use of electrocautery knife and
1.9-mm spiked forceps to obtain lymph node tissue to be safe
and more effective in detection of granulomatous disease and
provided larger specimens for clinical studies. However, it
is worth of noting that EBUS-TBNA had higher sensitivity
for detecting malignancy than EBUS-cautery assisted TBFB
(ca-TBFB) (27). Thus, these data overall support the idea
that EBUS-TBNA and EBUS-IFB are complementary
techniques in patient management. The relevant studies
pertaining to EBUS-IFB are summarized in Table 1.
Discussion
EBUS-TBNA has greatly altered the manner in which lung
cancer is diagnosed and staged. With advances in cancer
treatment, bronchoscopists are asked to provide increasing
amount of material for molecular testing in a safe and
minimally invasive way. As a complementary technique to
EBUS-TBNA, EBUS-IFB combines the EBUS guidance
with miniforceps biopsy to obtain histology specimen for
additional tissue acquisition. However, in clinical practice,
EBUS-IFB is underutilized. Several factors contribute
to the current state. One, lack of familiarity with EBUSIFB technique prohibit its use when EBUS-TBNA fails
to provide adequate samples. Two, with less clinical use,
physicians often fail to think of the indications that EBUS-
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Prospective
case series

Darwiche
2013 (24)

Patients:
55 (7 lost to
follow-up)

Patients: 50

Patients: 50

Patients:
50, lymph
node: 74

Patients: 75

Patients: 22

Number
subjects

Lymph node >10 mm.
TBNA (22G needle),
then needle forceps

PET avid mediastinal
lesions >15 mm.
Evaluation of needle
forceps (1.5 mm in
diameter) under EBUS

Lymph node stations
(4, 7, 10, 11, 12), size
mean of 18.7 mm.
EBUS-TBNA (22G
needle), EBUS-IFB

Subcarinal: 17,
paratracheal: 21, hilar:
36, lymph nodes (mean
=28 mm); sequential
EBUS-TBNA (22G
needle), EBUS-IFB

Subcarinal lymph node
(>25 mm); sequential
EBUS-TBNA (22G
needle), cTBNA (19G
needle), EBUS-IFB

Subcarinal lymph
node (>10 mm on CT);
cTBNA (19G needle);
IFB. Note: done under
fluoroscopy without
EBUS guidance

Criteria and technique

71% (TBNA),
83% (IFB*), 88%
(combined)

86% (IFB*)

50% (22G needle),
72% (IFB), 82%
(combined)

81% (22G needle),
91% (IFB), 97%
(combined)

36% (22G needle),
49% (19G needle),
88% (IFB)

45% (10/22
TBNA), 45%
(10/22 IFB), 55%
(combined)

Diagnostic yield

100% penetration rate.
Combined modality
increased diagnostic
yield of benign disease
from 64% to 93%

96% (48/50)
penetration rate with
needle forceps alone

Combined IFB with
TBNA increased yield
to 82.0% (41/50). IFB
size >3 mm provided
diagnosis in 90.9%

IFB lead to significant
increase in overall
diagnostic yield to
97%

IFB lead to significant
increase in diagnosis
of sarcoidosis
(88% vs. 36% for
TBNA, P=0.001) and
lymphoma (81% vs.
35%, P=0.038)

IFB provided diagnosis
for sarcoid (n=2),
where TBNA was
negative

Added value

None

None

3 cases of bleeding
controlled with local
epinephrine. 1 case of
pneumomediastinum.
1 case of atrial
fibrillation

None

None

One subclinical
pneumomediastinum
resolved without
intervention

Complication

IFB* (needle forceps) used in
conjunction with 22G needle.
Rigid bronchoscopy, general
anesthesia

IFB* (needle forceps) within 1.5
mm sheath, placed into lymph
node (mean size =22.7 mm).
Rigid bronchoscopy, general
anesthesia

IFB compared to TBNA
increased diagnostic yield
in disease other than lung
cancer (28 vs. 14). Rigid
bronchoscopy, general
anesthesia

No difference in benign
disease diagnosis. Increased
diagnosis in lymphoma, nonsmall cell and small cell.
Minimal added procedural
time. Flexible bronchoscopy,
moderate sedation

Samples are weighted
towards sarcoidosis (n=25,
33%) and lymphoma (n=26,
35%). Rigid bronchoscopy,
general anesthesia

Patient divided in 2 groups
[TBNA before IFB (n=11) vs.
IFB before TBNA (n=11)].
No comparison was done
between groups

Comments

*, needle miniforceps. IFB, intra-nodal forceps biopsy; TBNA, transbronchial needle aspiration; EBUS, endobronchial ultrasound; cTBNA, conventional transbronchial needle
aspiration.

Prospective
case series

Prospective
case series

Chrissian
2011 (21)

Herth
2012 (23)

Prospective
case series

Herth
2008 (20)

Prospective
case series

Prospective
case series

Oki 2004
(19)

Franke
2012 (22)

Design

Study

Table 1 Summary of intra-nodal forceps biopsy studies
Journal of Thoracic Disease, Vol 11, No 9 September 2019
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IFB should be considered. Three, unfamiliarity with the
equipment and the added cost of the miniforceps are
prohibitive for adoption in resource poor regions. EBUSTBNA has been widely adopted and most bronchoscopists
are familiar with the technique. As a complementary
procedure, EBUS-IFB may be well suited for several clinical
scenarios.
First, EBUS-IFB may be useful for cases in which
additional material is required for advanced molecular
analysis such as EGFR, ALK, PD-L1 testing or next
generation sequence testing. EBUS-IFB biopsies is
submitted as core specimens for processing. While some
institutional practices may be capable of performing these
assays using cytological specimens obtained by EBUSTBNA, this practice appears to be heterogeneous across
centers at the present time. Submitting core specimens in
addition to cytology specimens may improve the likelihood
for specimen adequacy for such tests, thereby obviating
the need for additional more invasive procedures, such
as mediastinoscopy or thoracoscopy. Of note, there is a
19-gauge EBUS needle for core sample acquisition. In a
recent study comparing 22- to 19-gauge needle for tissue
acquisition, the authors found similar diagnostic yield, but
19-gauge had more tissue by weight and more tumor cells
per sample (28). However, in a separate study, Chaddha
et al. noted that 19-gauge needle did not provide an
increase in diagnostic yield and the samples are often more
bloody (29). From our experience, blood contamination is
not an issue in EBUS-IFB. Of note, there is no comparison
of tissue acquisition between 19-gauge needle and IFB,
which remains an active area for clinical research. Additional
randomized controlled prospective studies will need to be
performed to ascertain the added value of the EBUS-IFB in
the era of molecular testing.
For diagnostic procedures such as in cases of suspected
lymphoma or sarcoidosis, combining EBUS-TBNA with
EBUS-IFB may improve the overall diagnostic yield of
bronchoscopy, without significantly increasing procedure
time or complications. While the difference in diagnostic
yield between EBUS-TBNA and EBUS-IFB was not
statistically significant (81% vs. 91%, respectively), the
combined yield of 97% for both procedures represented
a statistically significant improvement over EBUSTBNA alone, suggesting that EBUS-IFB may provide a
diagnosis in cases where EBUS-TBNA does not (21). This
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study supports the notion that the benefit of EBUS-IFB
is greatest when used as a complementary procedure to
EBUS-TBNA, not to be used as a replacement for EBUSTBNA. Additionally, the ability to provide a histology
specimen may enable pathologists to more readily identify
diagnostic elements in the lymph node (20). This may
be advantageous in centers with less experience using
EBUS-TBNA as learning curves for both bronchoscopists
and cytopathologists have been shown to influence the
diagnostic yield of procedures (30). Whether EBUS-IFB
is a superior technique to EBUS-TNBA remains to be
determined by future studies.
The influence of EBUS-IFB for lymphoma remains
unclear, due largely to the relatively small sample sizes
reported in available literature. Herth et al. reported in 75
patients an overall improvement in diagnostic yield using
EBUS-IFB, which was most pronounced in lymphoma cases
(81% vs. 35%, P=0.038) (20). In a separate study, EBUSIFB provided diagnosis of lymphoma in 4 of 4 (100%)
lymph nodes compared to 0 of 4 lymph nodes using EBUSTBNA (1 Hodgkin’s lymphoma and 3 non-Hodgkin’s
lymphoma) despite the use of flow cytometry in all cases. All
miniforceps samples were adequate to guide management
and all cases of lymphoma were new diagnoses (21). In
a recent study, EBUS-TBNA was able to diagnose and
subtype lymphoma in 67% (95% CI, 0.45–0.88) of patients
with de novo lymphoma and 81% (95% CI, 0.70–0.91) with
relapsed lymphoma (31). Taken these studies together,
in cases of suspected lymphoma, EBUS-IFB should be
considered in addition to EBUS-TBNA (Figure 6A,B).
EBUS-IFB was initially proposed as a method to improve
the overall diagnostic yield of bronchoscopy procedures.
While the yield of EBUS-TBNA remains excellent for the
diagnosis of carcinoma, challenges remain with increased
demand for additional tissue for advanced genetic testing
as well as the need to improve diagnostic yields for certain
conditions such as lymphoma, sarcoid, and infection
(Figure 6C,D). The bronchoscopists are faced with question
of how to accomplish additional tissue acquisition more
effectively, efficiently and safely using a minimally invasive
technique. We propose that EBUS-IFB be considered
for such instances and suggest that, when combined with
EBUS-TBNA, this technique may improve the overall
utility of bronchoscopy to provide diagnostic, staging and
specimen acquisition.
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Figure 6 EBUS-IFB in other etiologies. (A) Low magnification (H&E stain, 10×) of EBUS-IFB of follicular lymphoma; (B) high
magnification (H&E stain, 40×) of EBUS-IFB of follicular lymphoma; (C) high magnification (H&E stain, 40×) from EBUS-IFB of
sarcoidosis lesion; (D) Grocott’s methenamine silver stain highlights Histoplasma capsulatum obtained from EBUS-IFB (40×). EBUS,
endobronchial ultrasound; IFB, intranodal forceps biopsy; EBUS-IFB, EBUS-guided IFB.
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